Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. is conducting a Phase 4 clinical study titled ‘A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Subjects With Glucocorticoid-induced Osteoporosis in Mainland China.’ The study aims to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of the lumbar spine at month 12, focusing on participants with glucocorticoid-induced osteoporosis (GIOP).
The intervention being tested is Prolia®, a drug administered via subcutaneous injection every six months. It is designed to treat osteoporosis by increasing bone mass density.
This interventional study follows a single-group assignment model without masking, meaning all participants receive the treatment, and both researchers and participants are aware of the treatment being administered. The primary purpose is treatment-focused.
The study began on May 24, 2025, with the last update recorded on June 23, 2025. These dates are crucial as they indicate the study’s current recruiting status and ensure stakeholders are informed of its progress.
This study could influence Amgen’s stock performance positively if Prolia® demonstrates significant efficacy, potentially boosting investor confidence. Given the competitive landscape of osteoporosis treatments, successful results could position Amgen favorably against its competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.